FHL2 KO cell lysate available now. KO validated by Western blot. Free of charge wild type control included. Knockout achieved by using CRISPR/Cas9, 1 bp deletion in exon3 and 1 bp insertion in exon3.
Images
Key facts
- Cell type
- HeLa
- Species or organism
- Human
- Tissue
- Cervix
- Knockout validation
- Sanger Sequencing, Western blot
- Mutation description
- Knockout achieved by using CRISPR/Cas9, 1 bp deletion in exon3 and 1 bp insertion in exon3.
Alternative names
AAG 11, Aging associated gene 11, DRAL, Down regulated in rhabdomyosarcoma LIM protein, FHL2 protein, FHL2_HUMAN, Four and a half LIM domain protein 2, Four and a half LIM domains 2, Four and a half LIM domains protein 2, KIAA0990, LIM domain protein DRAL, SLIM-3, Skeletal muscle LIM-protein 3
What's included?
Recommended products
FHL2 KO cell lysate available now. KO validated by Western blot. Free of charge wild type control included. Knockout achieved by using CRISPR/Cas9, 1 bp deletion in exon3 and 1 bp insertion in exon3.
Key facts
- Cell type
- HeLa
- Species or organism
- Human
- Tissue
- Cervix
- Knockout validation
- Sanger Sequencing, Western blot
- Mutation description
- Knockout achieved by using CRISPR/Cas9, 1 bp deletion in exon3 and 1 bp insertion in exon3.
- Disease
- Adenocarcinoma
- Concentration
Properties
- Gene name
- FHL2
- Gene editing type
- Knockout
- Gene editing method
- CRISPR technology
- Knockout validation
- Sanger Sequencing, Western blot
Quality control
- STR analysis
- CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX
Cell culture
- Biosafety level
- EU: 2 US: 2
- Adherent/suspension
- Adherent
- Gender
- Female
Storage
- Shipped at conditions
- Ambient - Can Ship with Ice
- Appropriate short-term storage conditions
- -20°C
- Appropriate long-term storage conditions
- -20°C
Notes
Knockout cell lysate achieved by CRISPR/Cas9.
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation: Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10). This means that the protein of interest is denatured. If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions: Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our limited use license and patent pages.
Supplementary info
- This supplementary information is collated from multiple sources and compiled automatically.
- Activity summary
The FHL2 protein also known as Four and a Half LIM Domains Protein 2 plays an important role in cellular mechanics. Its molecular mass is approximately 32 kDa. FHL2 is expressed in various tissues with significant presence in cardiac and skeletal muscles as well as the liver. It is involved in the regulation of gene expression by binding to other proteins and DNA through its LIM domains. This ability allows FHL2 to influence cellular structures and functions integrally.
- Biological function summary
The FHL2 protein serves critical functions in muscle development and differentiation. It operates as part of a multiprotein complex that interacts with cytoskeletal components contributing importantly to muscle cell adhesion and communication. Moreover FHL2 engages in transcriptional regulation and acts as a coactivator or corepressor of specific transcription factors influencing gene expression patterns relevant to muscle function and maintenance.
- Pathways
The FHL2 protein plays significant roles in Wnt and MAPK signaling pathways. In the Wnt signaling pathway FHL2 regulates the transcriptional activity of beta-catenin an essential component of the pathway involved in cell growth and differentiation. Additionally FHL2 contributes to the MAPK signaling pathway by influencing interactions between upstream regulators and downstream targets modulating cellular responses to external stimuli. Through these pathways FHL2 interacts with various proteins including GATA4 and TEF-1 which are vital for its regulatory functions.
- Associated diseases and disorders
FHL2 has associations with certain cancers like prostate cancer and cardiomyopathy. In prostate cancer FHL2 overexpression leads to increased tumor progression and is often linked to androgen receptors promoting malignant transformation. In cardiomyopathy alterations in FHL2 expression affect heart muscle integrity and function sometimes in conjunction with interactions involving desmin an important structural protein. Understanding FHL2's connections to these diseases offers insights into potential therapeutic targets.
Product promise
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
4 product images
Western blot - Human FHL2 knockout HeLa cell lysate (ab257441)
Lane 1: Wild-type HeLa cell lysate (20 μg)Lane 2: FHL2 knockout HeLa cell lysate (20 μg)
Lane 3: K562 cell lysate (20 μg)
Lanes 1-3: Merged signal (red and green). Green - Anti-FHL2 antibody [EPR17860-23] ab202586 observed at 32 kDa. Red - loading control Anti-alpha Tubulin antibody [DM1A] - Loading Control ab7291 observed at 50 kDa.
Anti-FHL2 antibody [EPR17860-23] ab202586 Recombinant Anti-FHL2 antibody [EPR17860-23] was shown to specifically react with FHL2 in wild-type HeLa cells. Loss of signal was observed when knockout cell line Human FHL2 knockout HeLa cell line ab265475 (knockout cell lysate ab257441) was used. Wild-type and FHL2 knockout samples were subjected to SDS-PAGE. Anti-FHL2 antibody [EPR17860-23] ab202586 and Anti-alpha Tubulin antibody [DM1A] - Loading Control (Anti-alpha Tubulin antibody [DM1A] - Loading Control ab7291) were incubated overnight at 4°C at 1 in 1000 dilution and 1 in 20000 dilution respectively. Blots were developed with Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed (Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed ab216773) and Goat anti-Mouse IgG H&L (IRDye® 680RD) preadsorbed (Goat anti-Mouse IgG H&L (IRDye® 680RD) preadsorbed ab216776) secondary antibodies at 1 in 20000 dilution for 1 hour at room temperature before imaging.
All lanes: Western blot - Anti-FHL2 antibody [EPR17860-23] (Anti-FHL2 antibody [EPR17860-23] ab202586) at 1/1000 dilution
Lane 1: Wild-type HeLa lysate at 20 µg
Lane 2: FHL2 knockout HeLa lysate at 20 µg
Lane 2: Western blot - Human FHL2 knockout HeLa cell line (Human FHL2 knockout HeLa cell line ab265475)
Lane 3: K562 lysate at 20 µg
Performed under reducing conditions.
Predicted band size: 32 kDa
Observed band size: 32 kDa
Western blot - Human FHL2 knockout HeLa cell lysate (ab257441)
Lane 1: Wild-type HeLa cell lysate (20 μg)Lane 2: FHL2 knockout HeLa cell lysate (20 μg)
Lane 3: K562 cell lysate (20 μg)
Lanes 1-3: Merged signal (red and green). Green - Anti-FHL2 antibody [EPR17860-20] ab202584 observed at 32 kDa. Red - loading control Anti-alpha Tubulin antibody [DM1A] - Loading Control ab7291 observed at 50 kDa.
Anti-FHL2 antibody [EPR17860-20] ab202584 Recombinant Anti-FHL2 antibody [EPR17860-20] was shown to specifically react with FHL2 in wild-type HeLa cells. Loss of signal was observed when knockout cell line Human FHL2 knockout HeLa cell line ab265475 (knockout cell lysate ab257441) was used. Wild-type and FHL2 knockout samples were subjected to SDS-PAGE. Anti-FHL2 antibody [EPR17860-20] ab202584 and Anti-alpha Tubulin antibody [DM1A] - Loading Control?(Anti-alpha Tubulin antibody [DM1A] - Loading Control ab7291) were incubated overnight at 4^°C at 1 in 1000 dilution and 1 in 20000 dilution respectively. Blots were developed with Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed (Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed ab216773) and Goat anti-Mouse IgG H&L (IRDye® 680RD) preadsorbed (Goat anti-Mouse IgG H&L (IRDye® 680RD) preadsorbed ab216776) secondary antibodies at 1 in 20000 dilution for 1 hour at room temperature before imaging.
All lanes: Western blot - Anti-FHL2 antibody [EPR17860-20] (Anti-FHL2 antibody [EPR17860-20] ab202584) at 1/1000 dilution
Lane 1: Wild-type HeLa lysate at 20 µg
Lane 2: FHL2 knockout HeLa lysate at 20 µg
Lane 2: Western blot - Human FHL2 knockout HeLa cell line (Human FHL2 knockout HeLa cell line ab265475)
Lane 3: K562 lysate at 20 µg
Performed under reducing conditions.
Predicted band size: 32 kDa
Sanger Sequencing - Human FHL2 knockout HeLa cell lysate (ab257441)
Allele-1: 1 bp insertion in exon3
Sanger Sequencing - Human FHL2 knockout HeLa cell lysate (ab257441)
Allele-2: 1 bp deletion in exon3
Downloads
Product protocols
- Visit the general protocols
- Visit troubleshooting
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com